T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
MetadataShow full item record
BACKGROUND: Patients with metastatic sarcomas have poor outcomes and although the disease may be amenable to immunotherapies, information regarding the immunologic profiles of soft tissue sarcoma (STS) subtypes is limited. METHODS: The authors identified patients with the common STS subtypes: leiomyosarcoma, undifferentiated pleomorphic sarcoma (UPS), synovial sarcoma (SS), well-differentiated/dedifferentiated liposarcoma, and myxoid/round cell liposarcoma. Gene expression, immunohistochemistry for programmed cell death protein (PD-1) and programmed death-ligand 1 (PD-L1), and T-cell receptor Vβ gene sequencing were performed on formalin-fixed, paraffin-embedded tumors from 81 patients. Differences in liposarcoma subsets also were evaluated. RESULTS: UPS and leiomyosarcoma had high expression levels of genes related to antigen presentation and T-cell infiltration. UPS were found to have higher levels of PD-L1 (P≤.001) and PD-1 (P≤.05) on immunohistochemistry and had the highest T-cell infiltration based on T-cell receptor sequencing, significantly more than SS, which had the lowest (P≤.05). T-cell infiltrates in UPS also were more oligoclonal compared with SS and liposarcoma (P≤.05). A model adjusted for STS histologic subtype found that for all sarcomas, T-cell infiltration and clonality were highly correlated with PD-1 and PD-L1 expression levels (P≤.01). CONCLUSIONS: In the current study, the authors provide the most detailed overview of the immune microenvironment in sarcoma subtypes to date. UPS, which is a more highly mutated STS subtype, provokes a substantial immune response, suggesting that it may be well suited to treatment with immune checkpoint inhibitors. The SS and liposarcoma subsets are less mutated but do express immunogenic self-antigens, and therefore strategies to improve antigen presentation and T-cell infiltration may allow for successful immunotherapy in patients with these diagnoses. Cancer 2017;123:3291-304. © 2017 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Version of record
programmed cell death protein (PD-1)
programmed death-ligand 1 (PD-L1)
Aged, 80 and over
Analysis of Variance
Combined Modality Therapy
Gene Expression Regulation, Neoplastic
Programmed Cell Death 1 Receptor
Soft Tissue Neoplasms
Sarcoma Clinical Trials (R Jones)
License start date
Cancer, 2017, 123 (17), pp. 3291 - 3304
Showing items related by title, author, creator and subject.
Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent. van Erp, AEM; Versleijen-Jonkers, YMH; Hillebrandt-Roeffen, MHS; van Houdt, L; Gorris, MAJ; van Dam, LS; Mentzel, T; Weidema, ME; Savci-Heijink, CD; Desar, IME; Merks, HHM; van Noesel, MM; Shipley, J; van der Graaf, WTA; Flucke, UE; Meyer-Wentrup, FAG (2017-07-07)In order to explore the potential of immune checkpoint blockade in sarcoma, we investigated expression and clinical relevance of programmed cell death-1 (PD-1), programmed death ligand-1 (PD-L1) and CD8 in tumors of 208 ...
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. Arce Vargas, F; Furness, AJS; Solomon, I; Joshi, K; Mekkaoui, L; Lesko, MH; Miranda Rota, E; Dahan, R; Georgiou, A; Sledzinska, A; Ben Aissa, A; Franz, D; Werner Sunderland, M; Wong, YNS; Henry, JY; O'Brien, T; Nicol, D; Challacombe, B; Beers, SA; Melanoma TRACERx Consortium; Renal TRACERx Consortium; Lung TRACERx Consortium; Turajlic, S; Gore, M; Larkin, J; Swanton, C; Chester, KA; Pule, M; Ravetch, JV; Marafioti, T; Peggs, KS; Quezada, SACD25 is expressed at high levels on regulatory T (Treg) cells and was initially proposed as a target for cancer immunotherapy. However, anti-CD25 antibodies have displayed limited activity against established tumors. We ...
Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. Flynn, MJ; Larkin, JMG (2017-10)INTRODUCTION: Immune-checkpoint inhibitor (ICPI) drugs, which include antibodies against CTLA-4, PD-1 and PD-L1, have been shown to induce durable complete responses in a proportion of patients with particular efficacy ...